Garth Lees-Rolfe - Jan 21, 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Role: Chief Financial Officer
Signature: /s/ Garth Lees-Rolfe
Stock symbol: IKT
Transactions as of: Jan 21, 2025
Transactions value $: $0
Form type: 4
Date filed: 1/22/2025, 04:05 PM
Previous filing: Jan 7, 2025
Next filing: Jun 26, 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IKT	Stock Option (Right to Buy)	Disposed to Issuer	$0	-5.83K	-100%	$0.00	0	Jan 21, 2025	Common Stock	5.83K	$3.79	Direct	F1, F2
transaction	IKT	Stock Option (Right to Buy)	Award	$0	+5.83K		$0.00	5.83K	Jan 21, 2025	Common Stock	5.83K	$1.26	Direct	F1, F2
transaction	IKT	Stock Option (Right to Buy)	Disposed to Issuer	$0	-90K	-100%	$0.00	0	Jan 21, 2025	Common Stock	90K	$2.16	Direct	F1, F2
transaction	IKT	Stock Option (Right to Buy)	Award	$0	+90K		$0.00	90K	Jan 21, 2025	Common Stock	90K	$1.26	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
F2	This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.

Content

The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.

This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.